Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Biochemical Kinase Assay from US Patent US11840535: "Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity"
Assay data:25 Active, 25 Activity ≤ 1 µM, 25 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition of SIK; Abl and Src Kinases by Other Kinase Inhibitor from US Patent US20230348453: "HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF"
Assay data:29 Active, 29 Activity ≤ 1 µM, 29 Tested
C-abl Kinase Assay from US Patent US20230339978: "COMPOUNDS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS"
Assay data:29 Active, 2 Activity ≤ 1 nM, 29 Activity ≤ 1 µM, 29 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Biochemical Kinase Assay from US Patent US11746110: "Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity"
Assay data:16 Active, 1 Activity ≤ 1 nM, 16 Activity ≤ 1 µM, 16 Tested
c-Abl Kinase Assay from US Patent US11744824: "2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds"
Assay data:10 Active, 10 Activity ≤ 1 µM, 10 Tested
Measurement of c-Abl1, c-Abl2 and c-Kit IC50 Values from US Patent US11725005: "Compositions and methods for inhibiting kinases"
Assay data:43 Active, 43 Activity ≤ 1 µM, 43 Tested
Enzyme-linked immunosorbent assay (ELISA) from US Patent US11655239: "Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof"
Assay data:32 Active, 18 Activity ≤ 1 nM, 32 Activity ≤ 1 µM, 32 Tested
TBD from US Patent US11649218: "C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same"
Assay data:57 Active, 24 Activity ≤ 1 µM, 81 Tested
D3R2026 from Article : "Drug Design Data Resource Grand Challenge 3 Dataset: ABL1"
Assay data:2 Active, 1 Activity ≤ 1 µM, 2 Tested
Inhibition of full-length N-terminal His-tagged human c-Abl kinase (2 to 1130 residues) expressed in baculovirus expression system using Tk-substrate preincubated for 5 to 10 mins followed by substrate addition and measured after 40 mins by HTRF assay
Assay data:12 Active, 23 Activity ≤ 1 µM, 26 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of full-length N-terminal His-tagged human c-Abl kinase (2 to 1130 residues) expressed in baculovirus expression system using Tk-substrate preincubated for 5 to 10 mins followed by substrate addition at 1 uM and measured after 40 mins by HTRF assay relative to control
Assay data:26 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of Bcr-Abl (unknown origin)
Assay data:1 Active, 3 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of Abl T3151 (unknown origin)
Assay data:1 Active, 1 Tested
Inhibition of Abl (unknown origin)
Selectivity interaction (KinomeScan (DiscoverX, competition-binding assay)) EUB0000596aBDA ABL1
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Selectivity interaction (Kinase panel) EUB0000596aBDA ABL1
SummaryCompounds, ActiveRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on